TY - JOUR
T1 - DES Strut Thickness and Clinical Outcomes After CTO Recanalization
T2 - Insights From LATAM CTO Registry
AU - Câmara, Sérgio F.
AU - Campos, Carlos M.
AU - Machado, Rodrigo D.
AU - Padilla, Lucio
AU - Tinoco, João
AU - Botelho, Antonio Carlos
AU - Santiago, Ricardo
AU - Echavarria, Mauro
AU - de los Santos, Felix Damas
AU - Oliveira, Marcos Danillo P.
AU - Abelin, Anibal P.
AU - Perez, Luiz
AU - de Oliveira, Pedro P.
AU - Ribeiro, Marcelo H.
AU - Brilakis, Emmanouil S.
AU - Abizaid, Alexandre
AU - Quadros, Alexandre
N1 - Publisher Copyright:
© 2023
PY - 2023/8
Y1 - 2023/8
N2 - Background: Ultra-thin strut drug-eluting stent (UTS-DES) may improve outcomes after percutaneous coronary intervention (PCI) but have received limited study in chronic total occlusion (CTO) PCI. Aims: To compare of 1-year incidence of major adverse cardiac events (MACE) between patients who underwent CTO PCI with ultrathin (≤ 75 μm) versus thin (>75 μm) strut DES in the LATAM CTO registry. Methods: Patients were considered for inclusion only if successful CTO PCI was performed and when only one type of stent strut thickness (ultrathin or thin) was used. A propensity score matching (PSM) was computed to produce similar groups in relation to clinical and procedural characteristics. Results: Between January 2015 and January 2020, 2092 patients underwent CTO PCI, of whom 1466 were included in the present analysis (475 in the ultra-thin and 991 in the thin strut DES). In unadjusted analysis the UTS-DES group had lower rate of MACE (HR: 0.63 95 % CI 0.42 to 0.94, p = 0.04) and repeat revascularizations (HR: 0.50 95 % CI 0.31 to 0.81, p = 0.02) at 1-year follow-up. After adjustment for confounding factors in a Cox regression model there was no difference in 1-year incidence of MACE between groups (HR: 1.15 95 % CI 0.41 to 2.97, p = 0.85). On PSM of 686 patients (343 in each group) the 1-year incidence of MACE (HR 0.68 95 % CI 0.37–1.23; P = 0.22) and individual components of MACE did not differ between groups. Conclusions: One-year clinical outcomes after CTO PCI were similar with ultrathin and thin strut DES.
AB - Background: Ultra-thin strut drug-eluting stent (UTS-DES) may improve outcomes after percutaneous coronary intervention (PCI) but have received limited study in chronic total occlusion (CTO) PCI. Aims: To compare of 1-year incidence of major adverse cardiac events (MACE) between patients who underwent CTO PCI with ultrathin (≤ 75 μm) versus thin (>75 μm) strut DES in the LATAM CTO registry. Methods: Patients were considered for inclusion only if successful CTO PCI was performed and when only one type of stent strut thickness (ultrathin or thin) was used. A propensity score matching (PSM) was computed to produce similar groups in relation to clinical and procedural characteristics. Results: Between January 2015 and January 2020, 2092 patients underwent CTO PCI, of whom 1466 were included in the present analysis (475 in the ultra-thin and 991 in the thin strut DES). In unadjusted analysis the UTS-DES group had lower rate of MACE (HR: 0.63 95 % CI 0.42 to 0.94, p = 0.04) and repeat revascularizations (HR: 0.50 95 % CI 0.31 to 0.81, p = 0.02) at 1-year follow-up. After adjustment for confounding factors in a Cox regression model there was no difference in 1-year incidence of MACE between groups (HR: 1.15 95 % CI 0.41 to 2.97, p = 0.85). On PSM of 686 patients (343 in each group) the 1-year incidence of MACE (HR 0.68 95 % CI 0.37–1.23; P = 0.22) and individual components of MACE did not differ between groups. Conclusions: One-year clinical outcomes after CTO PCI were similar with ultrathin and thin strut DES.
KW - Chronic total occlusion (CTO)
KW - Major adverse cardiac events (MACE), ultrathin struts DES, thin struts DES
KW - Percutaneous coronary intervention (PCI)
UR - http://www.scopus.com/inward/record.url?scp=85149842152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149842152&partnerID=8YFLogxK
U2 - 10.1016/j.carrev.2023.03.002
DO - 10.1016/j.carrev.2023.03.002
M3 - Article
C2 - 36907696
AN - SCOPUS:85149842152
SN - 1553-8389
VL - 53
SP - 28
EP - 35
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
ER -